
|Articles|July 1, 2006
- Special Issues-07-01-2006
- Volume 0
- Issue 0
Party's Over
Pharmaceutical marketing and sales folks are now contending within creased government scrutiny of direct-to-consumer advertising and pharma-doctor relationships.
Advertisement
Articles in this issue
almost 20 years ago
Analytical Instrument Qualificationalmost 20 years ago
GMP and Phase I Clinical Trials: Streamlining the Critical Path?almost 20 years ago
Team Effortalmost 20 years ago
Rated PG: Pharmaceutical Guidance Suggestedalmost 20 years ago
European Clinical Trial Regulations Undergo a Slow Revolutionalmost 20 years ago
Moving Biotech Products from CBER to CDER: A Work in Progressalmost 20 years ago
FDA Video Interview Conducted by Jill Wechsler, Washington Bureau Chiefalmost 20 years ago
New Climatealmost 20 years ago
2006: A Regulatory OdysseyAdvertisement
Advertisement
Advertisement
Trending on LCGC International
1
ASMS 2026 Award Winners Highlight the Future of Mass Spectrometry
2
Best of the Week: Chromatography Methods, HPLC 2026 Previews, and More
3
A Look at the Major Technical Themes of ASMS 2026
4
HPLC 2026 Preview: Bo Zhang on Moving Towards Precision Design and Manufacture of Chromatographic Materials
5




